Clinical Trial Alert: Phase 3 Study of ALXN1720 in Adults with Generalized Myasthenia Gravis (gMG)

Researchers at Alexion AZ Rare Disease are seeking adults living with generalized myasthenia gravis (gMG) to participate in a phase 3 clinical trial (PREVAIL Study) to evaluate the safety and efficacy of ALXN1720 (gefurulimab) to treat gMG. ALXN1720 is being evaluated for the ability to improve the activities of daily living (ADL) of people with gMG.

In this study, participants will be randomly assigned to receive either the ALXN1720 or an inactive placebo control. The study duration will be 26 weeks, followed by an open-label extension period of 105 weeks. Regular study visits will be required on a schedule outlined by the study doctor/team.

The drug/placebo will be administered by subcutaneous (under the skin) injection. The effects of ALXN1720 will be evaluated using a number of outcome measures, including: Myasthenia Gravis-Activities of Daily Living (MG-ADL), the Quantitative Myasthenia Gravis (QMG), and Myasthenia Gravis Composite (MGC). The safety, stability, and tolerability of ALXN1720 will also be assessed using laboratory testing.

To be eligible, individuals must meet the following inclusion criteria:

• At least 18 years of age
• Have a confirmed diagnosis of myasthenia gravis (MG)
• Positive serological test for autoantibodies against AChR

Individuals may not be eligible to participate if they are affected by another illness or receiving another treatment that might interfere with the ability to undergo safe testing.

Please visit this link for the full listing of inclusion and exclusion criteria.

Travel support is available for eligible participants.

To learn more about the study or inquire about participation, please visit the study website or contact the study coordinator Christine Rowe by email: patientadvocacy@alexion.com.